Gradman W S, Cohen W, Haji-Aghaii M
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
J Vasc Surg. 2001 May;33(5):968-75. doi: 10.1067/mva.2001.115000.
The National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines favor autogenous vein for arteriovenous fistulas (AVFs). This report describes our experience constructing AVFs in the lower extremities of selected patients with the superficial femoral vein (SFV).
This is a retrospective analysis of 25 patients who had AVF construction with SFV from March 1998 to July 2000. In all patients upper extremity access had been exhausted. Eighteen (72%) patients were female, 15 (60%) had diabetes, and 14 (56%) were obese (body mass index > 30 kg/m(2)). The SFV was freed from the supragenicular popliteal level to the profunda femoris vein and divided distally. Eighteen (72%) patients had SFV transposition and distal superficial femoral artery reimplantation; 10 veins were banded to reduce the incidence of postoperative steal syndrome. In seven patients (28%) a composite loop fistula was constructed with a deeply buried 4- to 7-mm polytetrafluoroethylene (PTFE) graft proximally and with superficially transposed SFV distally. One of these seven patients had a PTFE above-knee femoral-popliteal bypass graft with banding of the vein at its takeoff from the distal PTFE graft.
Mean follow-up was 9.1 months. One patient died before the fistula could be used. Seven patients (28%) experienced major wound complications. Mean ankle/brachial index before operation was 1.03, and after operation it was 0.81 (paired difference [n = 16] = -0.26.) Mean ankle circumference before operation was 19.5 cm, and after operation it was 20.7 cm (paired difference [n = 17] = +0.87.) Cumulative primary fistula patency at 6 and 12 months was 78% and 73%, respectively. Cumulative secondary fistula patency at 6 and 12 months was 91% and 86%, respectively. There were no fistula infections. One patient eventually had an above-knee amputation after experiencing an acute compartment syndrome. Eight patients required a second operation to alleviate a symptomatic steal syndrome.
The SFV is an excellent conduit for vascular access, whether it is transposed or is part of a composite PTFE-SFV fistula. In this series, fistula infection was nonexistent, thrombosis rates were low, and clinical evidence of venous hypertension was minimal. The major impediment to unrestricted use of SFV in constructing AVFs is a high incidence of clinically significant postoperative ischemia requiring reoperation.
美国国家肾脏基金会-透析预后质量倡议指南倾向于使用自体静脉建立动静脉内瘘(AVF)。本报告描述了我们在选定患者的下肢使用股浅静脉(SFV)建立AVF的经验。
这是一项对1998年3月至2000年7月期间25例行SFV AVF建立术患者的回顾性分析。所有患者上肢血管通路均已用尽。18名(72%)患者为女性,15名(60%)患有糖尿病,14名(56%)肥胖(体重指数>30kg/m²)。将SFV从腘窝上缘游离至股深静脉并在远端离断。18名(72%)患者行SFV转位及股浅动脉远端再植术;10条静脉进行绑扎以降低术后窃血综合征的发生率。7名(28%)患者构建了复合袢内瘘,近端使用深埋的4至7mm聚四氟乙烯(PTFE)移植物,远端使用转位至浅表的SFV。这7名患者中有1名在PTFE膝上股-腘动脉旁路移植物处,在静脉从远端PTFE移植物发出处进行了绑扎。
平均随访9.1个月。1名患者在瘘管可用之前死亡。7名(28%)患者发生了严重的伤口并发症。术前平均踝/臂指数为1.03,术后为0.81(配对差值[n = 16] = -0.26)。术前平均踝周径为19.5cm,术后为20.7cm(配对差值[n = 17] = +0.87)。6个月和12个月时原发性内瘘的累积通畅率分别为78%和73%。6个月和12个月时继发性内瘘的累积通畅率分别为91%和86%。没有发生内瘘感染。1名患者在发生急性骨筋膜室综合征后最终接受了膝上截肢术。8名患者需要二次手术以缓解有症状的窃血综合征。
SFV无论是转位还是作为复合PTFE-SFV内瘘的一部分,都是血管通路的优良管道。在本系列中,不存在内瘘感染,血栓形成率低,静脉高压的临床证据极少。在构建AVF时,限制SFV无限制使用的主要障碍是术后发生具有临床意义的缺血且需要再次手术的发生率较高。